Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654927 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
A Phase 3 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT00654927 is a Phase 3 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 177 participants.
The verdict
NCT00654927, a Phase 3 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics or an Elan Corporation sponsored protocol. Subjects are eligible regardless of whether they received active drug or placebo during their participation in the previous study.
Interventions
- DRUG Fampridine-SR b.i.d. (Twice Daily)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2003-11 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654927
The ClinicalTrials.gov registry entry for NCT00654927 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fampridine-SR b.i.d. (Twice Daily) is the first listed.
NCT00654927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654927 about?
NCT00654927 is a clinical study titled "Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis". The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics or an Elan Corporation sponsored protocol. Subjects are eligible regardless of whether they ...
What is the current status of trial NCT00654927?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2003-11. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00654927?
The interventions under investigation include: Fampridine-SR b.i.d. (Twice Daily) (DRUG).
Who is sponsoring clinical trial NCT00654927?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.